Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn

04 Sep 2025 11:36 CEST

HBC is delighted to announce the appointment of Paul Bruhn as Head of New
Business Development. Mr Bruhn has over 25 years' experience in healthcare and
the medical nutrition space spanning Novartis Medical Nutrition and Nestle
Health Science.

He has been leading businesses across multiple geographies including Japan,
Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and
hence has an excellent overlap with corporates focused on developing the next
generation of products targeting clinical nutrition and consumer healthcare.

Mr Bruhn has significant experience working within the medical nutrition, VMS
and meal replacement categories, across multiple channels.

Mr Bruhn says:

"I am delighted to contribute to the journey of taking HBC to the next level,
particularly given the acceleration of business in Asia, China and across the
ANZ region. I believe there is a market need for new clinically backed sources
of nutrition, and the specialty ingredients from Hofseth BioCare fill that gap.

HBC has developed a unique portfolio of bioactive ingredients called OmeGo®,
ProGo®, NT-II(TM) and PetGo®, derived from salmon, that are backed by science
and
are fully sustainable, ensuring that the whole salmon is fully utilized. For
example, OmeGo®, unlike regular highly processed Omega 3 fish oils, is a full
spectrum salmon oil containing all the Omega fatty acids found in fresh whole
fish, is 100% natural and proven to be more absorbable with clinical evidence to
support anti-inflammation, supports heart health & has anti-allergy benefits.
These ingredients will ensure differentiation in large product categories that
are craving for innovation. I look forward to help putting them into leading
brands."

For further information, please contact:

James Berger, CCO at Hofseth BioCare ASA
Phone: +41 79 950 1034
E-mail: jb@hofsethbiocare.no

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health company founded on the core values of
sustainability, optimal utilization of natural resources and full traceability.
It upcycles the side streams of the salmon industry by taking fresh filleted
salmon and converting it from a waste product into ingredients to improve human
and pet health.

These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®,
a whole salmon oil, with all the fatty acid fractions contained in fish, and
CalGo® / NT-II® salmon bone powder containing calcium hydroxyapatite and
undenatured collagen for bone and joint health.

HBC places scientific evidence at the forefront which has led to important
academic partnerships and the identification of unique health benefits. This
includes the demonstration of improved iron metabolism by boosting the body's
ability to take up and use iron resulting in increased energy and vitality with
ProGo® as well as the activation of the GLP-1 receptor with fat reduction in
overweight adults. OmeGo® has shown important immune health benefits including
recovery from viral infection and improved respiratory health and sleep in
adults troubled by particulate matter pollution. Finally, CalGo® has shown both
bone and joint health benefits to support healthy ageing and active lifestyles.

This work has also resulted in the granting of a number of patents protecting
these discoveries. It has also led to the discovery of potential therapeutics
and HBC has spun out a biotech-focused company, HBC Immunology (HBCI) has raised
external finance, and the lead program is in prostate cancer followed by ovarian
cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for
asthma. HBC's headquarters are in Ålesund, Norway with branches in Oslo, London,
Zürich, Los Angeles and Palo Alto.

HBC is listed on Oslo Stock Exchange with ticker "HBC".

More information:
Access the news on Oslo Bors NewsWeb site